Illumina, Inc. (NASDAQ:ILMN) Receives $199.12 Average PT from Analysts

Illumina, Inc. (NASDAQ:ILMN) has earned a consensus rating of “Hold” from the eighteen brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $199.1250.

A number of analysts have recently commented on the stock. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. Citigroup lifted their price target on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Stifel Nicolaus boosted their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. increased their price objective on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Argus lifted their target price on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd.

Illumina Stock Performance

ILMN opened at $239.62 on Friday. The business’s 50-day moving average price is $204.62 and its two-hundred day moving average price is $165.80. Illumina has a 1 year low of $88.00 and a 1 year high of $250.06. The company has a market capitalization of $36.18 billion, a price-to-earnings ratio of 44.71, a P/E/G ratio of 3.47 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts expect that Illumina will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, Director Keith A. Meister sold 119,501 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the sale, the director directly owned 770,350 shares of the company’s stock, valued at $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,062,465 shares of company stock worth $436,589,802 over the last ninety days. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

Large investors have recently modified their holdings of the stock. Fiduciary Financial Advisors acquired a new position in Illumina in the 2nd quarter valued at about $26,000. MCF Advisors LLC boosted its holdings in shares of Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 100 shares during the period. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the second quarter valued at approximately $32,000. Rakuten Securities Inc. bought a new position in shares of Illumina during the second quarter worth approximately $33,000. Finally, Elyxium Wealth LLC bought a new position in shares of Illumina during the fourth quarter worth approximately $25,000. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.